Mehmet Gültekin, Murat Boyacıoğlu, Hasan Erdoğan, Kerem Ural, Hüseyin Voyvoda, Gamze Gültekin, Gizem Gönülveren, Onur Yılmazer, Ece Eylül Sönmez
{"title":"Pharmacokinetics, Amino Acid Responses, and Short-Term Tolerability of Intravenous and Oral L-Citrulline in Healthy Neonatal Holstein Calves.","authors":"Mehmet Gültekin, Murat Boyacıoğlu, Hasan Erdoğan, Kerem Ural, Hüseyin Voyvoda, Gamze Gültekin, Gizem Gönülveren, Onur Yılmazer, Ece Eylül Sönmez","doi":"10.1111/jvp.70101","DOIUrl":null,"url":null,"abstract":"<p><p>L-citrulline is a precursor for endogenous arginine synthesis, supporting nitric oxide production and urea cycle function, yet its pharmacokinetics in neonatal calves are unknown. This study characterized and compared the pharmacokinetics of L-citrulline after intravenous (IV) and oral (PO) administration in healthy neonatal Holstein calves and evaluated associated amino acid responses and short-term clinical and laboratory tolerability. Six healthy male calves (2-4 weeks old) received a single 150 mg/kg dose of L-citrulline as extemporaneously prepared 5% (w/v) IV and 10% (w/v) PO formulations in a randomized 2-period crossover design with a 7-day washout. Blood samples were collected pre-dose and up to 48 h post-dose. Plasma amino acids were quantified by LC-MS/MS, and pharmacokinetic parameters were estimated using non-compartmental analysis. After IV administration, the highest observed total plasma L-citrulline concentration was detected at the first post-dose sampling time, 5 min after bolus administration (C<sub>peak</sub> 2213 ± 629 μmol/L; range, 1329-2830 μmol/L). After PO administration, C<sub>max</sub> was 1107 ± 371 μmol/L (range, 623-1478 μmol/L), with a median T<sub>max</sub> of 60 min (range, 45-120 min). Baseline-corrected non-compartmental analysis yielded t<sub>1/2</sub> values of 2.32 ± 0.79 h after IV administration and 2.23 ± 0.60 h after PO administration, with AUC<sub>0-∞</sub> values of 4130 ± 558 and 3444 ± 1067 μmol·h/L, respectively. Absolute oral bioavailability was 0.86 ± 0.32 (range, 0.52-1.28). Both routes increased plasma arginine (max +159% IV; +122% PO) and ornithine (max +132% IV; +149% PO) with no clinically relevant adverse effects or laboratory abnormalities during short-term monitoring of clinical, hematological, biochemical, blood gas/electrolyte, and coagulation variables. These findings support further evaluation of L-citrulline as a nutritional and/or therapeutic supplement in neonatal calves.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jvp.70101","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
L-citrulline is a precursor for endogenous arginine synthesis, supporting nitric oxide production and urea cycle function, yet its pharmacokinetics in neonatal calves are unknown. This study characterized and compared the pharmacokinetics of L-citrulline after intravenous (IV) and oral (PO) administration in healthy neonatal Holstein calves and evaluated associated amino acid responses and short-term clinical and laboratory tolerability. Six healthy male calves (2-4 weeks old) received a single 150 mg/kg dose of L-citrulline as extemporaneously prepared 5% (w/v) IV and 10% (w/v) PO formulations in a randomized 2-period crossover design with a 7-day washout. Blood samples were collected pre-dose and up to 48 h post-dose. Plasma amino acids were quantified by LC-MS/MS, and pharmacokinetic parameters were estimated using non-compartmental analysis. After IV administration, the highest observed total plasma L-citrulline concentration was detected at the first post-dose sampling time, 5 min after bolus administration (Cpeak 2213 ± 629 μmol/L; range, 1329-2830 μmol/L). After PO administration, Cmax was 1107 ± 371 μmol/L (range, 623-1478 μmol/L), with a median Tmax of 60 min (range, 45-120 min). Baseline-corrected non-compartmental analysis yielded t1/2 values of 2.32 ± 0.79 h after IV administration and 2.23 ± 0.60 h after PO administration, with AUC0-∞ values of 4130 ± 558 and 3444 ± 1067 μmol·h/L, respectively. Absolute oral bioavailability was 0.86 ± 0.32 (range, 0.52-1.28). Both routes increased plasma arginine (max +159% IV; +122% PO) and ornithine (max +132% IV; +149% PO) with no clinically relevant adverse effects or laboratory abnormalities during short-term monitoring of clinical, hematological, biochemical, blood gas/electrolyte, and coagulation variables. These findings support further evaluation of L-citrulline as a nutritional and/or therapeutic supplement in neonatal calves.
期刊介绍:
The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.